Li Z J, Zhang P, Zhang W, Zhang Z, Wang X M, Xiao C H
The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin 300060, China.
Zhonghua Zhong Liu Za Zhi. 2018 Sep 23;40(9):690-695. doi: 10.3760/cma.j.issn.0253-3766.2018.09.011.
To explore the oncological safety of immediate breast reconstruction after nipple-areola complex(NAC) sparing mastectomy(NSM+ IBR) in patients with early stage breast cancer, and to analyze the prognostic factors of NSM+ IBR. From January 2004 to December 2015, the clinical data of 118 cases of stage Ⅰ-ⅡA breast cancer who had undergone NSM+ IBR in Tianjin Tumor Hospital were collected, comparing with 75 cases of Ⅰ-ⅡA breast cancer patients who had undergone immediate breast reconstruction after modified radical mastectomy (MRM+ IBR) at the same period. In addition to the prognosis of these two groups, the prognostic factors were also retrospectively analyzed. The median follow-up were 53 months in the NSM+ IBR group and 51 months in the MRM+ IBR group, respectively. In the NSM+ IBR group, local recurrence, distant metastasis, death and NAC necrosis occurred in 4, 6, 9 and 4 cases during 3 years after operation, respectively. The local recurrence rate (LRR) was 3.4%, 3-year disease-free survival (DFS) rate was 91.5%, and the overall survival (OS) rate was 92.4%. In the MRM+ IBR group, local recurrence, distant metastasis, and death occurred in 1, 4, and 3 cases during 3 years after operation, respectively. The LRR was 1.3%, 3-year DFS was 93.3%, whereas the OS rate was 96.0%. No statistical difference was noted between the two groups (all >0.05). That HER-2 positive and molecular type correlated with the 3-year DFS (<0.05) independently and molecular type correlated with OS (<0.05) independently in the NSM+ IBR group. NSM does not impair patients' prognosis and could ensure oncological safety of patients with early stage breast cancer. IBR could improve female patients' figure and ensure the quality of life. HER-2 status and molecular type are the independent prognostic factors of the 3-year DFS. Molecular type is the independent prognosis factor of OS.
探讨早期乳腺癌患者保留乳头乳晕复合体的乳房切除术后即刻乳房重建(NSM+IBR)的肿瘤学安全性,并分析NSM+IBR的预后因素。收集2004年1月至2015年12月在天津肿瘤医院接受NSM+IBR的118例Ⅰ-ⅡA期乳腺癌患者的临床资料,并与同期75例接受改良根治术后即刻乳房重建(MRM+IBR)的Ⅰ-ⅡA期乳腺癌患者进行比较。除分析两组患者的预后情况外,还对预后因素进行回顾性分析。NSM+IBR组的中位随访时间为53个月,MRM+IBR组为51个月。NSM+IBR组术后3年内分别有4例、6例、9例和4例发生局部复发、远处转移、死亡和乳头乳晕复合体坏死。局部复发率(LRR)为3.4%,3年无病生存率(DFS)为91.5%,总生存率(OS)为92.4%。MRM+IBR组术后3年内分别有1例、4例和3例发生局部复发、远处转移和死亡。LRR为1.3%,3年DFS为93.3%,OS率为96.0%。两组之间差异无统计学意义(均>0.05)。在NSM+IBR组中,HER-2阳性和分子类型分别独立与3年DFS相关(<0.05),分子类型独立与OS相关(<0.05)。保留乳头乳晕复合体的乳房切除术不影响患者预后,可确保早期乳腺癌患者的肿瘤学安全性。即刻乳房重建可改善女性患者外形,保证生活质量。HER-2状态和分子类型是3年DFS的独立预后因素。分子类型是OS的独立预后因素。